How Reactive Metabolites Induce an Immune Response That Sometimes Leads to an Idiosyncratic Drug Reaction
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Little is known with certainty about the mechanisms of idiosyncratic drug reactions (IDRs); however, there is substantive evidence that reactive metabolites are involved in most, but not all, IDRs. In addition, evidence also suggests that most IDRs are immune mediated. That raises the question of how reactive metabolites induce an immune response that can lead to an IDR. The dominant hypotheses are the hapten and danger hypotheses. These are complementary hypotheses: a reactive metabolite can act as a hapten to produce neoantigens, and it can also cause cell damage leading to the release of danger-associated molecular pattern molecules that activate antigen presenting cells. Both are required for an immune response. In addition, drugs may induce an immune response through inflammasome activation. We have found examples in which the ability to activate inflammasomes differentiated drugs that cause IDRs from similar drugs that do not. There are other hypotheses that do not involve an immune mechanism such as mitochondrial injury and bile salt export pump (BSEP) inhibition. With some possible exceptions, these hypotheses are unlikely to be able to completely explain IDRs. However, some types of mitochondrial injury or BSEP inhibition could produce danger signals. The major mechanism that protects us from IDRs appears to be immune tolerance. Consistent with this hypothesis, we used checkpoint inhibition to develop the first animal model of idiosyncratic drug-induced liver injury that has the same characteristics as the idiosyncratic injury in humans. This was accomplished by treating Pd-1 –/– mice with anti-CTLA-4 antibodies and amodiaquine. The combination of the Pd-1 –/– mouse and anti-CTLA-4 also unmasks the ability of other drugs such as isoniazid to cause delayed type liver injury. This model should allow rigorous testing of mechanistic hypotheses that was impossible in the past.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yang, H., Lundbäck, P., Ottosson, L., Erlandsson-Harris, H., Venereau, E., Bianchi, M. E., Al-Abed, Y., Andersson, U., Tracey, K. J., & Antoine, D. J. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00389 · Cited by 407
RetractedMartinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
Inflammasomes: mechanism of action, role in disease, and therapeutics
Guo, H., Callaway, J. B., & Ting, J. P.-Y. (2015) · Nature Medicine · doi:10.1038/nm.3893 · Cited by 3,340
Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response
Bertolotti, A., Zhang, Y., Hendershot, L. M., Harding, H. P., & Ron, D. (2000) · Nature Cell Biology · doi:10.1038/35014014 · Cited by 2,860
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
ER stress-induced cell death mechanisms
Sano, R., & Reed, J. C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.06.028 · Cited by 1,988
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768
Endotoxin tolerance: new mechanisms, molecules and clinical significance
Biswas, S. K., & Lopez-Collazo, E. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.07.009 · Cited by 1,318
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987
NLRP3 inflammasome and its inhibitors: a review
Shao, B.-Z., Xu, Z.-Q., Han, B.-Z., Su, D.-F., & Liu, C. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00262 · Cited by 836
McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331702 · Cited by 616
Bile Acid Transporters: Structure, Function, Regulation and Pathophysiological Implications
Alrefai, W. A., & Gill, R. K. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9289-1 · Cited by 500
Mechanisms of inflammasome activation: recent advances and novel insights
Vanaja, S. K., Rathinam, V. A. K., & Fitzgerald, K. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.12.009 · Cited by 499
2,4-Dinitrophenol (DNP): A Weight Loss Agent with Significant Acute Toxicity and Risk of Death
Grundlingh, J., Dargan, P. I., El-Zanfaly, M., & Wood, D. M. (2011) · Journal of Medical Toxicology · doi:10.1007/s13181-011-0162-6 · Cited by 470
Immune tolerance: What is unique about the liver
Tiegs, G., & Lohse, A. W. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.08.008 · Cited by 394
Labbe, G., Pessayre, D., & Fromenty, B. (2008) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00608.x · Cited by 317
Horst, A. K., Neumann, K., Diehl, L., & Tiegs, G. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.112 · Cited by 295
Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones.
Schnyder, B., Mauri-Hellweg, D., Zanni, M., Bettens, F., & Pichler, W. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119505 · Cited by 281
Safety Review of Adult Clinical Trial Experience with Lamotrigine
Messenheimer, J., Mullens, E. L., Giorgi, L., & Young, F. (1998) · Drug Safety · doi:10.2165/00002018-199818040-00004 · Cited by 252
Aleo, M. D., Luo, Y., Swiss, R., Bonin, P. D., Potter, D. M., & Will, Y. (2014) · Hepatology · doi:10.1002/hep.27206 · Cited by 215
Characterization of lidocaine-specific T cells
Zanni, M. P., Mauri-Hellweg, D., Brander, C., Wendland, T., Schnyder, B., Frei, E., von Greyerz, S., Bircher, A., & Pichler, W. J. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1139 · Cited by 138
Chakraborty, M., Fullerton, A. M., Semple, K., Chea, L. S., Proctor, W. R., Bourdi, M., Kleiner, D. E., Zeng, X., Ryan, P. M., Dagur, P. K., et al. (2015) · Hepatology · doi:10.1002/hep.27764 · Cited by 64
Hepatotoxicity of nucleoside reverse transcriptase inhibitors
(2003) · Seminars in Liver Disease · doi:10.1055/s-2003-39947 · Cited by 62
Lee, K. K., & Boelsterli, U. A. (2014) · Redox Biology · doi:10.1016/j.redox.2014.03.003 · Cited by 57
Cited by
Reproducing human and cross-species drug toxicities using a liver-chip
Jang, K.-J., Otieno, M. A., Ronxhi, J., Lim, H.-K., Ewart, L., Kodella, K. R., Petropolis, D. B., Kulkarni, G., Rubins, J. E., Conegliano, D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax5516 · Cited by 511
“This exemplifies the advantage of the Liver-Chip for assessing the pathophysiological consequence of reactive metabolite formation, which has been strongly associated with idiosyncratic DILI (37, 54, 55).”
BackgroundA missense variant in PTPN22 is a risk factor for drug-induced liver injury
Cirulli, E. T., Nicoletti, P., Abramson, K., Andrade, R. J., Bjornsson, E. S., Chalasani, N., Fontana, R. J., Hallberg, P., Li, Y. J., Lucena, M. I., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.034 · Cited by 137
Drug-induced liver injury: Highlights of the recent literature
Real, M., Barnhill, M. S., Higley, C., Rosenberg, J., & Lewis, J. H. (2019) · Drug Safety · doi:10.1007/s40264-018-0743-2 · Cited by 103
Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism
Lazarska, K. E., Dekker, S. J., Vermeulen, N. P. E., & Commandeur, J. N. M. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2017.11.038 · Cited by 55
Mechanisms of idiosyncratic drug-induced liver injury
Uetrecht, J. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2018.12.001 · Cited by 49
Self-citation
Metadata
- Authors
- Cho, T., & Uetrecht, J.
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-11-08
- Volume
- 30
- Issue
- 1
- Pages
- 295-314
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- OpenAlex
- W2536091639
- Cited by
- 150
- References
- 26
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.